130 related articles for article (PubMed ID: 205658)
21. Calcium-dependent phosphodiesterase from male mouse germ cells: functional properties and characterization of the enzyme.
Giorgi M; Geremia R; Kincaid RL; Rossi P
Ital J Biochem; 1989; 38(4):261A-263A. PubMed ID: 2555313
[No Abstract] [Full Text] [Related]
22. Multiplicity within cyclic nucleotide phosphodiesterases.
Rybalkin SD; Beavo JA
Biochem Soc Trans; 1996 Nov; 24(4):1005-9. PubMed ID: 8968501
[No Abstract] [Full Text] [Related]
23. Recovery of quenched radioactivity from thin-layer chromatographic plates. An improved assay for cGMP phosphodiesterase in Myxococcus xanthus.
Ho J; Warner AH; McCurdy HD
J Biochem; 1980 Sep; 88(3):659-62. PubMed ID: 6252204
[TBL] [Abstract][Full Text] [Related]
24. Analysis of cyclic nucleotide phosphodiesterase(s) by radioimmunoassay.
Sarada K; Epstein PM; Strada SJ; Thompson WJ
Arch Biochem Biophys; 1982 Apr; 215(1):183-98. PubMed ID: 6284039
[No Abstract] [Full Text] [Related]
25. Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form.
Lavan BE; Lakey T; Houslay MD
Biochem Pharmacol; 1989 Nov; 38(22):4123-36. PubMed ID: 2480793
[TBL] [Abstract][Full Text] [Related]
26. A sensitive cyclic nucleotide phosphodiesterase assay for transient enzyme kinetics.
Van Lookeren Campagne MM; Van Haastert PJ
Anal Biochem; 1983 Nov; 135(1):146-50. PubMed ID: 6322611
[TBL] [Abstract][Full Text] [Related]
27. The enzymatic preparation of [alpha-32P]ATP, [alpha-32P]GTP, [32P]cAMP, and [32P]cGMP, and their use in the assay of adenylate and guanylate cyclases and cyclic nucleotide phosphodiesterases.
Johnson RA; Walseth TF
Adv Cyclic Nucleotide Res; 1979; 10():135-67. PubMed ID: 36738
[No Abstract] [Full Text] [Related]
28. Phosphodiesterase inhibitors as tools in cyclic nucleotide research: a precautionary comment.
Wells JN; Kramer GL
Mol Cell Endocrinol; 1981 Jul; 23(1):1-9. PubMed ID: 6167475
[No Abstract] [Full Text] [Related]
29. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta. A study with selective inhibitors.
Schoeffter P; Lugnier C; Demesy-Waeldele F; Stoclet JC
Biochem Pharmacol; 1987 Nov; 36(22):3965-72. PubMed ID: 2825708
[TBL] [Abstract][Full Text] [Related]
30. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from the cytosol of human platelets.
Grant PG; Mannarino AF; Colman RW
Thromb Res; 1990 Jul; 59(1):105-19. PubMed ID: 2169075
[TBL] [Abstract][Full Text] [Related]
31. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation.
Rybalkin SD; Bornfeldt KE
Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733
[No Abstract] [Full Text] [Related]
32. Cyclic nucleotide phosphodiesterase in the aorta of spontaneously hypertensive rats : variation with age and effect of propranolol.
Bucher B; Stoclet JC
Artery; 1980; 7(1):44-55. PubMed ID: 6264899
[TBL] [Abstract][Full Text] [Related]
33. Changes of cyclic-AMP and cycic-AMP phosphodiesterase in the progression and regression of experimental atherosclerosis.
Numano F; Maezawa H
Ann N Y Acad Sci; 1976; 275():311-20. PubMed ID: 188369
[No Abstract] [Full Text] [Related]
34. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
35. Involvement of calcium in cyclic nucleotide metabolism in human vascular smooth muscle.
Hidaka H; Yamaki T; Asano M; Totsuka T
Blood Vessels; 1978; 15(1-3):55-64. PubMed ID: 204383
[TBL] [Abstract][Full Text] [Related]
36. Distribution of cyclic nucleotide phosphodiesterase in mouse brain.
Yang MS; Passonneau P; Lowry OH
J Neurochem; 1981 Mar; 36(3):1272-8. PubMed ID: 6259285
[TBL] [Abstract][Full Text] [Related]
37. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
Küthe A; Montorsi F; Andersson KE; Stief CG
Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
[TBL] [Abstract][Full Text] [Related]
38. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
39. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of the effects of sodium nitroprusside and of isoproterenol by selective phosphodiesterase inhibitors.
Lorenz KL; Wells JN
Mol Pharmacol; 1983 Mar; 23(2):424-30. PubMed ID: 6300651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
